tei 9647 profile

TEI 9647: a 1alpha,25-dihydroxyvitamin D3 antagonist; TEI-9647 is the (23S)-isomer, and TEI-9648 is the (23R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9547692
CHEMBL ID	383902
CHEBI ID	156177
SCHEMBL ID	14489024
MeSH ID	M0351333

Synonym
(23s)-1alpha-hydroxy-25,27-didehydrovitamin d3 26,23-lactone
LMST03020599 ,
(5z,7e)-(1s,3r,23s)-1,3-dihydroxy-9,10-seco-5,7,10(19),25(27)-cholestatetraeno-26,23-lactone
gtpl2788
tei9647
tei 9647
tei-9647
CHEMBL383902 ,
(5s)-5-[(2r)-2-[(1r,3as,4e,7ar)-4-[(2z)-2-[(3s,5r)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]propyl]-3-methylideneoxolan-2-one
CHEBI:156177
(23s)-1-hydroxy-25,27-didehydrovitamin d3 26,23-lactone
bdbm50411169
SCHEMBL14489024
173388-20-0
HY-12398
tel9647
Q27088957
9,10-secocholesta-5,7,10(19),25(27)-tetraen-26-oic acid, 1,3,23-trihydroxy-, gamma-lactone, (1alpha,3beta,5z,7e,23s)-
CS-0011253
MS-27532
2(3h)-furanone, 5-[(2r)-2-[(1r,3as,4e,7ar)-4-[(2z)-2-[(3s,5r)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1h-inden-1-yl]propyl]dihydro-3-methylene-, (5s)-
AKOS040742705

Excerpt	Relevance	Reference
" Calcitriol inhibited the expression profile of inflammatory cytokine genes in a dose-response manner (P<0."	( Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. Avila, E; Barrera, D; Díaz, L; Halhali, A; Hernández, G; Larrea, F; Noyola-Martínez, N, 2009)	0.35

Class	Description
vitamin D	Any member of a group of fat-soluble hydroxy seco-steroids that exhibit biological activity against vitamin D deficiency. Vitamin D can be obtained from sun exposure, food and supplements and is biologically inactive and converted into the biologically active calcitriol via double hydroxylation in the body.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vitamin D3 receptor	Homo sapiens (human)	IC50 (µMol)	0.0063	0.0000	0.4374	6.4300	AID272633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of DNA-templated transcription	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
cell morphogenesis	Vitamin D3 receptor	Homo sapiens (human)
skeletal system development	Vitamin D3 receptor	Homo sapiens (human)
calcium ion transport	Vitamin D3 receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	Vitamin D3 receptor	Homo sapiens (human)
lactation	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of gene expression	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of keratinocyte proliferation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activity	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of bone mineralization	Vitamin D3 receptor	Homo sapiens (human)
phosphate ion transmembrane transport	Vitamin D3 receptor	Homo sapiens (human)
bile acid signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
decidualization	Vitamin D3 receptor	Homo sapiens (human)
intestinal absorption	Vitamin D3 receptor	Homo sapiens (human)
apoptotic process involved in mammary gland involution	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involution	Vitamin D3 receptor	Homo sapiens (human)
regulation of calcidiol 1-monooxygenase activity	Vitamin D3 receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Vitamin D3 receptor	Homo sapiens (human)
vitamin D receptor signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of vitamin D receptor signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
response to bile acid	Vitamin D3 receptor	Homo sapiens (human)
multicellular organism development	Vitamin D3 receptor	Homo sapiens (human)
cell differentiation	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
DNA-binding transcription factor activity	Vitamin D3 receptor	Homo sapiens (human)
vitamin D response element binding	Vitamin D3 receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Vitamin D3 receptor	Homo sapiens (human)
DNA binding	Vitamin D3 receptor	Homo sapiens (human)
nuclear receptor activity	Vitamin D3 receptor	Homo sapiens (human)
protein binding	Vitamin D3 receptor	Homo sapiens (human)
zinc ion binding	Vitamin D3 receptor	Homo sapiens (human)
bile acid nuclear receptor activity	Vitamin D3 receptor	Homo sapiens (human)
nuclear retinoid X receptor binding	Vitamin D3 receptor	Homo sapiens (human)
calcitriol binding	Vitamin D3 receptor	Homo sapiens (human)
lithocholic acid binding	Vitamin D3 receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Vitamin D3 receptor	Homo sapiens (human)
nucleus	Vitamin D3 receptor	Homo sapiens (human)
nucleoplasm	Vitamin D3 receptor	Homo sapiens (human)
cytosol	Vitamin D3 receptor	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Vitamin D3 receptor	Homo sapiens (human)
chromatin	Vitamin D3 receptor	Homo sapiens (human)
receptor complex	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID260130	Inhibition of transactivation of human VDR in COS7 cells	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Vitamin D receptor: ligand recognition and allosteric network.
AID260131	Antagonistic activity against human VDR in presence of 1,25(OH)2D3	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Vitamin D receptor: ligand recognition and allosteric network.
AID272633	Antagonist activity against 1-alpha,25-dihydroxy vitamin D3-induced HL60 cell differentiation by NBT reduction method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2alpha-functionalization of 25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones.
AID272631	Displacement of [26,27-methyl-3H]1alpha,25-dihydroxy vitamin D3 from chick intestinal VDR relative to 1-alpha,25-dihydroxy vitamin D3	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2alpha-functionalization of 25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (8.00)	18.2507
2000's	18 (72.00)	29.6817
2010's	4 (16.00)	24.3611
2020's	1 (4.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (7.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (92.31%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	2.05	1	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.15	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	2.03	1	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.03	1	metal allergen; nickel group element atom; platinum group metal atom
chromium Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.	2.03	1	chromium group element atom; metal allergen	micronutrient
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.99	1	actinomycin	mutagen
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	7.12	25	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	4.03	4	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
3-ketolithocholic acid 3-ketolithocholic acid: structure in first source	2.03	1	oxo-5beta-cholanic acid
kh 1060 KH 1060: structure given in first source; a new 20-epi-vitamin D3 analog	2.03	1
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.02	1	cysteinium	fundamental metabolite
1,25-dihydroxyvitamin d3-26,23-lactone [no description available]	2	1	vitamin D
1,25(oh)2-16-ene-23-yne-d3 Ro 23-7553: very potent in inhibiting proliferation & inducing differentiation of myeloid leukemic cells in vitro	2	1
zk159222 ZK159222: a 25-carboxylic ester analog of 1alpha-25-dihydroxyvitamin D3; structure in first source	2.42	2	vitamin D

Condition	Relationship Strength	Studies
Dysmyelopoietic Syndromes [description not available]	2.15	1
Acute Myelogenous Leukemia [description not available]	2.15	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.15	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.15	1
Complications, Pregnancy [description not available]	2.05	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.46	2
Innate Inflammatory Response [description not available]	2.07	1
Edema-Proteinuria-Hypertension Gestosis [description not available]	2.07	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.07	1
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	2.07	1
Goldblatt Syndrome [description not available]	2.99	1
Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression.	2.99	1
Osteogenic Sarcoma [description not available]	2.42	2
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.42	2
Bone Loss, Osteoclastic [description not available]	2.42	2
Osseous Paget's Disease [description not available]	3.63	3
Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.	3.63	3
Milk-Alkali Syndrome [description not available]	2.94	1
Secondary Hyperparathyroidism [description not available]	2.94	1
Diseases of Immune System [description not available]	2.94	1
Benign Neoplasms [description not available]	2.94	1
Age-Related Osteoporosis [description not available]	2.94	1
Palmoplantaris Pustulosis [description not available]	2.94	1
Hypercalcemia Abnormally high level of calcium in the blood.	2.94	1
Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.	2.94	1
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	2.94	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.94	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.94	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.94	1
Acute Promyelocytic Leukemia [description not available]	2	1
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2	1
Deficiency, Vitamin D [description not available]	2	1
Vitamin D Deficiency A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)	2	1

tei 9647

Description

Cross-References

Synonyms (22)

Research Excerpts

Dosage Studied

Drug Classes (1)

Protein Targets (1)

Inhibition Measurements

Biological Processes (28)

Molecular Functions (12)

Ceullar Components (6)

Bioassays (4)

Research

Studies (25)

Market Indicators

Research Demand Index: 16.77

Study Types